Testing Patients For Chronic Kidney Disease (CKD)

Chronic (CKD) affects around 37 million Americans. Troubling research from AZ shows the prevalence of undiagnosed stage 3—moderate—CKD is 85% to 97%.  Dr. Ruud Dobber, executive vice president of the biopharmaceuticals business unit at AstraZeneca, said, “New real-world evidence data presented at ERA 2023 build on existing research to paint a stark picture: chronic kidney disease is a global public health emergency that needs to be tackled immediately.”  Addressing the problem will come by increasing focus on the disease among both physicians and patients.

Patient Communication from AstraZeneca

For a variety of reasons the disease can go undetected in the early stages, leading to series issues for patients. At first, there might be no noticeable symptoms, or the symptoms could be subtle and nonspecific, such as fatigue, slight changes in urine pattern, or mild swelling. As a result, individuals may not realize that there could be an issue with their kidneys. Therefore, they may not seek medical help or tests that could help diagnose the problem.   Without alerts from the patient, CKD may advance.

Patient communication and education programs can help patients understand their syptoms and increase awareness of the disease.  This will potentially help to trigger discussions with healthcare professionals.  AstraZeneca is developing patient communication programs, including direct to consumer (DTC) marketing campaigns to warn patients about the problem.

Diagnosing Chronic Kidney Disease.

If the patient expresses any concerns about kidney issues, healthcare providers are likely to conduct routine medical check-ups. During these check-ups, healthcare providers may order standard blood and urine tests to assess kidney function. These tests can reveal abnormalities in kidney function, even if the patient is not experiencing serious symptoms.

Breakthrough Testing from Renalytix

More advanced testing approaches are now also available to detect CKD among patients.  This year, Renalytix received FDA’s authorization for its prognostic test aimed at predicting an oncoming decline in kidney function.  AstraZeneca is working in cooperation with Renalytix to identify patients who are at risk along with improving adherence on therapy.  As the ability to detect CKD improves, the medical community will be able to diagnose patients at earlier stages.  This will result in better healthcare outcomes.